東華大學圖書館 |

語系: 繁體中文

說明(常見問題)

回圖書館首頁

手機版館藏查詢

登入

回首頁 到查詢結果 [ null ]

切換: 標籤 | MARC模式 | ISBD

Advancing the Discovery and Implemen...

Keat, Karl,

FindBook

Google Book

Amazon

博客來

Advancing the Discovery and Implementation of Pharmacogenomics Using Genomic Biobanks and Artificial Intelligence /

紀錄類型:	書目-電子資源 : Monograph/item
正題名/作者:	Advancing the Discovery and Implementation of Pharmacogenomics Using Genomic Biobanks and Artificial Intelligence // Karl Keat.
作者:	Keat, Karl,
面頁冊數:	1 electronic resource (109 pages)
附註:	Source: Dissertations Abstracts International, Volume: 86-12, Section: B.
Contained By:	Dissertations Abstracts International86-12B.
標題:	Bioinformatics. -
電子資源:	https://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=31993792
ISBN:	9798280759220

Advancing the Discovery and Implementation of Pharmacogenomics Using Genomic Biobanks and Artificial Intelligence /
Keat, Karl,

Advancing the Discovery and Implementation of Pharmacogenomics Using Genomic Biobanks and Artificial Intelligence /Karl Keat. - 1 electronic resource (109 pages)

Source: Dissertations Abstracts International, Volume: 86-12, Section: B.

While significant progress has been made in understanding the genetic underpinnings of drug response, clinical impact of these discoveries has been limited. Implementation of pharmacogenetics in routine care has been slow, and even when pharmacogenetic information is available for a patient, there are many un-accounted genetic and non-genetic factors which greatly influence drug response. To build evidence for the benefits of pharmacogenetic implementation, we used a large medical biobank to quantify rates of prescription for medications with known pharmacogenetic associations, as well as frequencies of pharmacogenetic variants. We demonstrated a high burden of pharmacogenetic variants, with many individuals receiving medication for which there were actionable pharmacogenetic guidelines based on their genetics. We also demonstrated that these burdens vary across ancestral populations, with certain populations disproportionately affected by specific variants. We then evaluated large language models (LLMs) as digital assistants for facilitating clinical pharmacogenetics. We built a comprehensive benchmark of pharmacogenetic questions and answers and used it to query several off-the-shelf models, discovering significant limitations that need to be accounted for before LLMs can be brought into the clinic. Lastly, we explored how summary statistics for external genome-wide association studies may be useful for building polygenic scores (PGS) for pharmacologic traits with low sample sizes. We used the AIDS Clinical Trials Group dataset to evaluate a multi-ancestry PGS for body mass index (BMI) which we repurposed towards predicting weight gain following antiretroviral therapy for HIV. While there was no association between genetic predisposition towards high BMI with increased weight gain, we successfully demonstrated the efficacy of our multi-ancestry BMI PGS in predicting BMI in a population of people living with HIV. Altogether, our results demonstrate avenues for improving pharmacogenetics both from the perspective of bringing existing knowledge into the clinic as well as generating new knowledge that transcends traditional monogenic pharmacogenetics.

English

ISBN: 9798280759220Subjects--Topical Terms:

553671
Bioinformatics.
Subjects--Index Terms:

Genomics

Advancing the Discovery and Implementation of Pharmacogenomics Using Genomic Biobanks and Artificial Intelligence /
LDR:03736nmm a22004453i 4500 001 2432302
005 20250707081339.5
006 m o d
007 cr|nu||||||||
008 261011s2025 miu||||||m |||||||eng d
020 $a 9798280759220
035 $a (MiAaPQD)AAI31993792
035 $a AAI31993792
040 $a MiAaPQD $b eng $c MiAaPQD $e rda
100 1 $a Keat, Karl, $e author. $3 3821468
245 1 0 $a Advancing the Discovery and Implementation of Pharmacogenomics Using Genomic Biobanks and Artificial Intelligence / $c Karl Keat.
264 1 $a Ann Arbor : $b ProQuest Dissertations & Theses, $c 2025
300 $a 1 electronic resource (109 pages)
336 $a text $b txt $2 rdacontent
337 $a computer $b c $2 rdamedia
338 $a online resource $b cr $2 rdacarrier
500 $a Source: Dissertations Abstracts International, Volume: 86-12, Section: B.
500 $a Advisors: Ritchie, Marylyn D.; Kim, Dokyoon Committee members: Long, Qi; Setia Verma, Shefali; Tuteja, Sony; Perera, Minoli.
502 $b Ph.D. $c University of Pennsylvania $d 2025.
520 $a While significant progress has been made in understanding the genetic underpinnings of drug response, clinical impact of these discoveries has been limited. Implementation of pharmacogenetics in routine care has been slow, and even when pharmacogenetic information is available for a patient, there are many un-accounted genetic and non-genetic factors which greatly influence drug response. To build evidence for the benefits of pharmacogenetic implementation, we used a large medical biobank to quantify rates of prescription for medications with known pharmacogenetic associations, as well as frequencies of pharmacogenetic variants. We demonstrated a high burden of pharmacogenetic variants, with many individuals receiving medication for which there were actionable pharmacogenetic guidelines based on their genetics. We also demonstrated that these burdens vary across ancestral populations, with certain populations disproportionately affected by specific variants. We then evaluated large language models (LLMs) as digital assistants for facilitating clinical pharmacogenetics. We built a comprehensive benchmark of pharmacogenetic questions and answers and used it to query several off-the-shelf models, discovering significant limitations that need to be accounted for before LLMs can be brought into the clinic. Lastly, we explored how summary statistics for external genome-wide association studies may be useful for building polygenic scores (PGS) for pharmacologic traits with low sample sizes. We used the AIDS Clinical Trials Group dataset to evaluate a multi-ancestry PGS for body mass index (BMI) which we repurposed towards predicting weight gain following antiretroviral therapy for HIV. While there was no association between genetic predisposition towards high BMI with increased weight gain, we successfully demonstrated the efficacy of our multi-ancestry BMI PGS in predicting BMI in a population of people living with HIV. Altogether, our results demonstrate avenues for improving pharmacogenetics both from the perspective of bringing existing knowledge into the clinic as well as generating new knowledge that transcends traditional monogenic pharmacogenetics.
546 $a English
590 $a School code: 0175
650 4 $a Bioinformatics. $3 553671
650 4 $a Genetics. $3 530508
650 4 $a Pharmacology. $3 634543
653 $a Genomics
653 $a Large language models
653 $a Pharmacogenetics
653 $a Pharmacogenomics
690 $a 0715
690 $a 0369
690 $a 0419
690 $a 0800
710 2 $a University of Pennsylvania. $b Genomics and Computational Biology. $e degree granting institution. $3 3821469
720 1 $a Ritchie, Marylyn D. $e degree supervisor.
720 1 $a Kim, Dokyoon $e degree supervisor.
773 0 $t Dissertations Abstracts International $g 86-12B.
790 $a 0175
791 $a Ph.D.
792 $a 2025
856 4 0 $u https://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=31993792